

# Stanford


---




## David Katzenstein

Professor (Research) of Medicine (Infectious Diseases and Geographic Medicine),  
Emeritus

Medicine - Infectious Diseases

 NIH Biosketch available Online

 Curriculum Vitae available Online

---

### Bio

#### ACADEMIC APPOINTMENTS

- Emeritus Faculty, Acad Council, Medicine - Infectious Diseases
- Member, Bio-X

#### HONORS AND AWARDS

- Distinguished Clinical Scientist Award, Doris Duke Charitable Trust (2000-2005)

#### LINKS

- AIDS Treatment in Africa: <http://www.med.stanford.edu/act-now>, <http://saturn4hiv.org>, <http://fightaidsnow.org>

---

### Research & Scholarship

#### CURRENT RESEARCH AND SCHOLARLY INTERESTS

Treatment and evaluation of HIV infection

#### CLINICAL TRIALS

- Consent for Use of Stored Patient Specimens for Future Testing, Recruiting
- Long-Term Data Collection From Participants in Adult AIDS Clinical Trials, Not Recruiting

---

### Teaching

#### COURSES

2016-17

- Alternative Spring Break: Confronting HIV/AIDS in San Francisco: MED 145 (Win)

---

### Publications

#### PUBLICATIONS

- **Community-based self-collected human papillomavirus screening in rural Zimbabwe.** *BMC public health*  
Fitzpatrick, M. B., El-Khatib, Z., Katzenstein, D., Pinsky, B. A., Chirenje, Z. M., McCarty, K.  
2019; 19 (Suppl 1): 603
- **hrHPV prevalence and type distribution in rural Zimbabwe: A community-based self-collection study using near-point-of-care GeneXpert HPV testing** *INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES*  
Fitzpatrick, M. B., Mandishora, R., Katzenstein, D. A., McCarty, K., Weber, J., Sahoo, M. K., Manasa, J., Chirenje, Z., Pinsky, B. A.

2019; 82: 21–29

- **Persistence of Human Immunodeficiency Virus-1 Drug Resistance Mutations in Proviral Deoxyribonucleic Acid After Virologic Failure of Efavirenz-Containing Antiretroviral Regimens** *OPEN FORUM INFECTIOUS DISEASES*  
De La Cruz, J., Vardhanbhuti, S., Sahoo, M. K., Rovner, R., Bosch, R. J., Manasa, J., Katzenstein, D. A., Pinsky, B. A.  
2019; 6 (3)
- **Persistence of Human Immunodeficiency Virus-1 Drug Resistance Mutations in Proviral Deoxyribonucleic Acid After Virologic Failure of Efavirenz-Containing Antiretroviral Regimens.** *Open forum infectious diseases*  
De La Cruz, J., Vardhanbhuti, S., Sahoo, M. K., Rovner, R., Bosch, R. J., Manasa, J., Katzenstein, D. A., Pinsky, B. A.  
2019; 6 (3): ofz034
- **Trends in Pretreatment HIV-1 Drug Resistance in Antiretroviral Therapy-naive Adults in South Africa, 2000-2016: A Pooled Sequence Analysis.** *EclinicalMedicine*  
Chimukangara, B., Lessells, R. J., Rhee, S., Giandhari, J., Kharsany, A. B., Naidoo, K., Lewis, L., Cawood, C., Khanyile, D., Ayalew, K. A., Diallo, K., Samuel, R., Hunt, et al  
2019; 9: 26–34
- **hrHPV Prevalence and Type Distribution in Rural Zimbabwe: A Community-Based Self-Collection Study using Near-Point-of-Care GeneXpert HPV testing.** *International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases*  
Fitzpatrick, M. B., Dube Mandishora, R. S., Katzenstein, D. A., McCarty, K., Weber, J., Sahoo, M. K., Manasa, J., Chirenje, Z. M., Pinsky, B. A.  
2019
- **Patterns of detectable viraemia among children and adults with HIV infection taking antiretroviral therapy in Zimbabwe** *INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES*  
Sovershaeva, E., Shamu, T., Wilsgaard, T., Bandason, T., Flaegstad, T., Katzenstein, D., Ferrand, R. A., Odland, J.  
2019; 78: 65–71
- **Combining Phylogenetic and Network Approaches to Identify HIV-1 Transmission Links in San Mateo County, California** *FRONTIERS IN MICROBIOLOGY*  
Dalai, S. C., Junqueira, D., Wilkinson, E., Mehra, R., Pond, S., Levy, V., Israelski, D., de Oliveira, T., Katzenstein, D.  
2018; 9
- **Patterns of detectable viraemia among children and adults with HIV infection taking antiretroviral therapy in Zimbabwe.** *International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases*  
Sovershaeva, E., Shamu, T., Wilsgaard, T., Bandason, T., Flagstad, T., Katzenstein, D., Ferrand, R. A., Odland, J.  
2018
- **HIV-1 Drug Resistance and Third-Line Therapy Outcomes in Patients Failing Second-Line Therapy in Zimbabwe** *OPEN FORUM INFECTIOUS DISEASES*  
Chimbetete, C., Katzenstein, D., Shamu, T., Spoerri, A., Estill, J., Egger, M., Keiser, O.  
2018; 5 (2): ofy005
- **Combining Phylogenetic and Network Approaches to Identify HIV-1 Transmission Links in San Mateo County, California.** *Frontiers in microbiology*  
Dalai, S. C., Junqueira, D. M., Wilkinson, E., Mehra, R., Kosakovsky Pond, S. L., Levy, V., Israelski, D., de Oliveira, T., Katzenstein, D.  
2018; 9: 2799
- **Community Based Antiretroviral Treatment in Rural Zimbabwe** *AIDS RESEARCH AND HUMAN RETROVIRUSES*  
Chimukangara, B., Manasa, J., Mitchell, R., Nyabadza, G., Katzenstein, D., Masimirembwa, C.  
2017; 33 (12): 1185–91
- **Defining a cut-off for atazanavir in hair samples associated with virological failure among adolescents failing second-line antiretroviral treatment.** *Journal of acquired immune deficiency syndromes*  
Chawana, T. D., Gandhi, M., Nathoo, K., Ngara, B., Louie, A., Horng, H., Katzenstein, D., Metcalfe, J., Brian Nhachi, C. F.  
2017
- **HIV drug resistance testing among patients failing second line antiretroviral therapy. Comparison of in-house and commercial sequencing** *JOURNAL OF VIROLOGICAL METHODS*  
Chimukangara, B., Varyani, B., Shamu, T., Mutsvangwa, J., Manasa, J., White, E., Chimbetete, C., Luethy, R., Katzenstein, D.  
2017; 243: 151-157

- **A Simple Phosphate-Buffered-Saline-Based Extraction Method Improves Specificity of HIV Viral Load Monitoring Using Dried Blood Spots.** *Journal of clinical microbiology*  
Makadzange, A. T., Boyd, F. K., Chimukangara, B., Masimirembwa, C., Katzenstein, D., Ndhlovu, C. E.  
2017; 55 (7): 2172–79
- **Evaluating an enhanced adherence intervention among HIV positive adolescents failing atazanavir/ritonavir-based second line antiretroviral treatment at a public health clinic.** *Journal of AIDS and HIV research (Online)*  
Chawana, T. D., Katzenstein, D., Nathoo, K., Ngara, B., Nhachi, C. F.  
2017; 9 (1): 17–30
- **Evolution of gag and gp41 in Patients Receiving Ritonavir-Boosted Protease Inhibitors.** *Scientific reports*  
Manasa, J., Varghese, V., Pond, S. L., Rhee, S. Y., Tzou, P. L., Fessel, W. J., Jang, K. S., White, E., Rögnvaldsson, T., Katzenstein, D. A., Shafer, R. W.  
2017; 7 (1): 11559
- **Collaborative update of a rule-based expert system for HIV-1 genotypic resistance test interpretation.** *PLoS one*  
Paredes, R., Tzou, P. L., van Zyl, G., Barrow, G., Camacho, R., Carmona, S., Grant, P. M., Gupta, R. K., Hamers, R. L., Harrigan, P. R., Jordan, M. R., Kantor, R., Katzenstein, et al  
2017; 12 (7): e0181357
- **HIV drug resistance testing among patients failing second line antiretroviral therapy. Comparison of in-house and commercial sequencing.** *Journal of virological methods*  
Chimukangara, B., Varyani, B., Shamu, T., Mutsvangwa, J., Manasa, J., White, E., Chimbete, C., Luethy, R., Katzenstein, D.  
2017; 243: 151–57
- **Evaluation of the Aptima HIV-1 Quant Dx Assay Using Plasma and Dried Blood Spots.** *Journal of clinical microbiology*  
Sahoo, M. K., Varghese, V., White, E., Winslow, M., Katzenstein, D. A., Shafer, R. W., Pinsky, B. A.  
2016; 54 (10): 2597-2601
- **Transmitted HIV Drug Resistance Is High and Longstanding in Metropolitan Washington, DC** *CLINICAL INFECTIOUS DISEASES*  
Kassaye, S. G., Grossman, Z., Balamane, M., Johnston-White, B., Liu, C., Kumar, P., Young, M., Sneller, M. C., Sereti, I., Dewar, R., Rehm, C., Meyer, W., Shafer, et al  
2016; 65 (6): 836-843
- **Transmitted HIV Drug Resistance Is High and Longstanding in Metropolitan Washington, DC.** *Clinical infectious diseases*  
Kassaye, S. G., Grossman, Z., Balamane, M., Johnston-White, B., Liu, C., Kumar, P., Young, M., Sneller, M. C., Sereti, I., Dewar, R., Rehm, C., Meyer, W., Shafer, et al  
2016; 63 (6): 836-843
- **Editorial Commentary: Scaling Up Antiretroviral Therapy in Africa: Are We There Yet?** *Clinical infectious diseases*  
Manasa, J., Katzenstein, D.  
2016; 62 (4): 519-520
- **Phenotype, Genotype, and Drug Resistance in Subtype C HIV-1 Infection** *JOURNAL OF INFECTIOUS DISEASES*  
Derache, A., Wallis, C. L., Vardhanabhuti, S., Bartlett, J., Kumarasamy, N., Katzenstein, D.  
2016; 213 (2): 250-256
- **Human Immunodeficiency Virus-1 Sequence Changes and Drug Resistance Mutation Among Virologic Failures of Lopinavir/Ritonavir Monotherapy: AIDS Clinical Trials Group Protocol A5230.** *Open forum infectious diseases*  
Vardhanabhuti, S., Katzenstein, D., Bartlett, J., Kumarasamy, N., Wallis, C. L.  
2016; 3 (3): ofw154
- **The cryptococcal antigen lateral flow assay: A point-of-care diagnostic at an opportune time** *CRITICAL REVIEWS IN MICROBIOLOGY*  
Tang, M. W., Clemons, K. V., Katzenstein, D. A., Stevens, D. A.  
2016; 42 (4): 634-642
- **Global Comparison of Drug Resistance Mutations After First-Line Antiretroviral Therapy Across Human Immunodeficiency Virus-1 Subtypes.** *Open forum infectious diseases*  
Huang, A., Hogan, J. W., Luo, X., DeLong, A., Saravanan, S., Wu, Y., Sirivichayakul, S., Kumarasamy, N., Zhang, F., Phanuphak, P., Diero, L., Buziba, N., Istrail, et al  
2016; 3 (2): ofv158

- **HIV-1 Drug Resistance Mutations: Potential Applications for Point-of-Care Genotypic Resistance Testing** *PLOS ONE*  
Rhee, S., Jordan, M. R., Raizes, E., Chua, A., Parkin, N., Kantor, R., van Zyl, G. U., Mukui, I., Hosseinipour, M. C., Frenkel, L. M., Ndembi, N., Hamers, R. L., de Wit, et al  
2015; 10 (12)
- **Sustainable HIV treatment in Africa through viral-load-informed differentiated care** *NATURE*  
Phillips, A., Shroufi, A., Vojnov, L., Cohn, J., Roberts, T., Ellman, T., Bonner, K., Rousseau, C., Garnett, G., Cambiano, V., Nakagawa, F., Ford, D., Bansi-Matharu, et al  
2015; 528 (7580): S68-S76
- **Lopinavir/Ritonavir Monotherapy as Second-line Antiretroviral Treatment in Resource-Limited Settings: Week 104 Analysis of AIDS Clinical Trials Group (ACTG) A5230** *CLINICAL INFECTIOUS DISEASES*  
Kumarasamy, N., Aga, E., Ribaudo, H. J., Wallis, C. L., Katzenstein, D. A., Stevens, W. S., Norton, M. R., Klingman, K. L., Hosseinipour, M. C., Crump, J. A., Supparatpinyo, K., Badal-Faesen, S., Bartlett, et al  
2015; 60 (10): 1552-1558
- **Geographic and temporal trends in the molecular epidemiology and genetic mechanisms of transmitted HIV-1 drug resistance: an individual-patient- and sequence-level meta-analysis.** *PLoS medicine*  
Rhee, S., Blanco, J. L., Jordan, M. R., Taylor, J., Lemey, P., Varghese, V., Hamers, R. L., Bertagnolio, S., Rinke de Wit, T. F., Aghokeng, A. F., Albert, J., Avi, R., Avila-Rios, et al  
2015; 12 (4)
- **Geographic and Temporal Trends in the Molecular Epidemiology and Genetic Mechanisms of Transmitted HIV-1 Drug Resistance: An Individual-Patient- and Sequence-Level Meta-Analysis.** *PLoS medicine*  
Rhee, S., Blanco, J. L., Jordan, M. R., Taylor, J., Lemey, P., Varghese, V., Hamers, R. L., Bertagnolio, S., de Wit, T. F., Aghokeng, A. F., Albert, J., Avi, R., Avila-Rios, et al  
2015; 12 (4)
- **Impact of Drug Resistance-Associated Amino Acid Changes in HIV-1 Subtype C on Susceptibility to Newer Nonnucleoside Reverse Transcriptase Inhibitors** *ANTIMICROBIAL AGENTS AND CHEMOTHERAPY*  
Basson, A. E., Rhee, S., Parry, C. M., El-Khatib, Z., Charalambous, S., de Oliveira, T., Pillay, D., Hoffmann, C., Katzenstein, D., Shafer, R. W., Morris, L.  
2015; 59 (2): 960-971
- **HIV Drug Resistance Mutations in Proviral DNA from a Community Treatment Program** *PLOS ONE*  
Derache, A., Shin, H., Balamane, M., White, E., Israelski, D., Klausner, J. D., Freeman, A. H., Katzenstein, D.  
2015; 10 (1)
- **Lopinavir/Ritonavir Monotherapy as Second-line Antiretroviral Treatment in Resource-Limited Settings: Week 104 Analysis of AIDS Clinical Trials Group (ACTG) A5230.** *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*  
Kumarasamy, N., Aga, E., Ribaudo, H. J., Wallis, C. L., Katzenstein, D. A., Stevens, W. S., Norton, M. R., Klingman, K. L., Hosseinipour, M. C., Crump, J. A., Supparatpinyo, K., Badal-Faesen, S., Bartlett, et al  
2015; 60 (10): 1552-58
- **Sustainable HIV treatment in Africa through viral-load-informed differentiated care.** *Nature*  
Phillips, A., Shroufi, A., Vojnov, L., Cohn, J., Roberts, T., Ellman, T., Bonner, K., Rousseau, C., Garnett, G., Cambiano, V., Nakagawa, F., Ford, D., Bansi-Matharu, et al  
2015; 528 (7580): S68-76
- **HIV-1 Drug Resistance Mutations: Potential Applications for Point-of-Care Genotypic Resistance Testing.** *PloS one*  
Rhee, S., Jordan, M. R., Raizes, E., Chua, A., Parkin, N., Kantor, R., van Zyl, G. U., Mukui, I., Hosseinipour, M. C., Frenkel, L. M., Ndembi, N., Hamers, R. L., Rinke de Wit, et al  
2015; 10 (12)
- **HIV diversity and drug resistance from plasma and non-plasma analytes in a large treatment programme in western Kenya** *JOURNAL OF THE INTERNATIONAL AIDS SOCIETY*  
Kantor, R., DeLong, A., Balamane, M., Schreier, L., Lloyd, R. M., Injera, W., Kamle, L., Mambo, F., Muyonga, S., Katzenstein, D., Hogan, J., Buziba, N., Diero, et al  
2014; 17
- **Drug Susceptibility and Resistance Mutations After First-Line Failure in Resource Limited Settings** *CLINICAL INFECTIOUS DISEASES*  
Wallis, C. L., Aga, E., Ribaudo, H., Saravanan, S., Norton, M., Stevens, W., Kumarasamy, N., Bartlett, J., Katzenstein, D.

2014; 59 (5): 706-715

- **Association between Latent Proviral Characteristics and Immune Activation in Antiretrovirus-Treated Human Immunodeficiency Virus Type 1-Infected Adults.** *Journal of virology*  
Liang, E. C., Sceats, L., Bayless, N. L., Strauss-Albee, D. M., Kubo, J., Grant, P. M., Furman, D., Desai, M., Katzenstein, D. A., Davis, M. M., Zolopa, A. R., Blish, C. A.  
2014; 88 (15): 8629-8639
- **Role of oral candidiasis in TB and HIV co-infection: AIDS Clinical Trial Group Protocol A5253** *INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE*  
Shiboski, C. H., Chen, H., Ghannoum, M. A., Komarow, L., Evans, S., Mukherjee, P. K., Isham, N., KATZENSTEIN, D., Asmelash, A., Omozoarhe, A. E., Gengiah, S., Allen, R., Tripathy, et al  
2014; 18 (6): 682-688
- **HIV-1 RNA Levels and Antiretroviral Drug Resistance in Blood and Non-Blood Compartments from HIV-1-Infected Men and Women enrolled in AIDS Clinical Trials Group Study A5077** *PLOS ONE*  
Kantor, R., Bettendorf, D., Bosch, R. J., Mann, M., Katzenstein, D., Cu-Uvin, S., D'Aquila, R., Frenkel, L., Fiscus, S., Coombs, R.  
2014; 9 (4)
- **Outcomes by Sex Following Treatment Initiation With Atazanavir Plus Ritonavir or Efavirenz With Abacavir/Lamivudine or Tenofovir/Emtricitabine** *CLINICAL INFECTIOUS DISEASES*  
Smith, K. Y., Tierney, C., Mollan, K., Venuto, C. S., Budhathoki, C., Ma, Q., Morse, G. D., Sax, P., Katzenstein, D., Godfrey, C., Fischl, M., Daar, E. S., Collier, et al  
2014; 58 (4): 555-563
- **HIV RNA and genotype in resource-limited settings: can we do better?** *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*  
Katzenstein, D. A.  
2014; 58 (1): 110-112
- **HIV diversity and drug resistance from plasma and non-plasma analytes in a large treatment programme in western Kenya.** *Journal of the International AIDS Society*  
Kantor, R., DeLong, A., Balamane, M., Schreier, L., Lloyd, R. M., Injera, W., Kamle, L., Mambo, F., Muyonga, S., Katzenstein, D., Hogan, J., Buziba, N., Diero, et al  
2014; 17: 19262
- **An affordable HIV-1 drug resistance monitoring method for resource limited settings.** *Journal of visualized experiments : JoVE*  
Manasa, J., Danaviah, S., Pillay, S., Padayachee, P., Mthiyane, H., Mkhize, C., Lessells, R. J., Seebregts, C., de Wit, T. F., Viljoen, J., Katzenstein, D., de Oliveira, T.  
2014
- **Drug Resistance Mutations from Whole Blood Proviral DNA Among Patients on Antiretroviral Drugs in Zimbabwe** *CURRENT HIV RESEARCH*  
Chimukangara, B., Gwanzura, L., Mitchell, R., Katzenstein, D., Masimirembwa, C.  
2014; 12 (5): 309-316
- **Early Virologic Response to Abacavir/Lamivudine and Tenofovir/Emtricitabine During ACTG A5202** *HIV CLINICAL TRIALS*  
Grant, P. M., Tierney, C., Budhathoki, C., Daar, E. S., Sax, P. E., Collier, A. C., Fischl, M. A., Zolopa, A. R., Balamane, M., Katzenstein, D.  
2013; 14 (6): 284-291
- **Prototypical Recombinant Multi-Protease-Inhibitor-Resistant Infectious Molecular Clones of Human Immunodeficiency Virus Type 1** *ANTIMICROBIAL AGENTS AND CHEMOTHERAPY*  
Varghese, V., Mitsuya, Y., Fessel, W. J., Liu, T. F., Melikian, G. L., Katzenstein, D. A., Schiffer, C. A., Holmes, S. P., Shafer, R. W.  
2013; 57 (9): 4290-4299
- **Capacity building and predictors of success for HIV-1 drug resistance testing in the Asia-Pacific region and Africa** *JOURNAL OF THE INTERNATIONAL AIDS SOCIETY*  
Land, S., Zhou, J., Cunningham, P., Sohn, A. H., Singtoroj, T., Katzenstein, D., Mann, M., Sayer, D., Kantor, R.  
2013; 16
- **Nucleoside reverse transcriptase inhibitor resistance mutations associated with first-line stavudine-containing antiretroviral therapy: programmatic implications for countries phasing out stavudine.** *journal of infectious diseases*

- Tang, M. W., Rhee, S., Bertagnolio, S., Ford, N., Holmes, S., Sigaloff, K. C., Hamers, R. L., de Wit, T. F., Fleury, H. J., Kanki, P. J., Ruxrungtham, K., Hawkins, C. A., Wallis, et al  
2013; 207: S70-7
- **Nucleoside reverse transcriptase inhibitor resistance mutations associated with first-line Stavudine-containing antiretroviral therapy: programmatic implications for countries phasing out Stavudine.** *journal of infectious diseases*  
Tang, M. W., Rhee, S., Bertagnolio, S., Ford, N., Holmes, S., Sigaloff, K. C., Hamers, R. L., de Wit, T. F., Fleury, H. J., Kanki, P. J., Ruxrungtham, K., Hawkins, C. A., Wallis, et al  
2013; 207: S70-7
  - **In vitro HIV-1 evolution in response to triple reverse transcriptase inhibitors & in silico phenotypic analysis.** *PloS one*  
Rath, B. A., Yousef, K. P., Katzenstein, D. K., Shafer, R. W., Schütte, C., von Kleist, M., Merigan, T. C.  
2013; 8 (4)
  - **In Vitro HIV-1 Evolution in Response to Triple Reverse Transcriptase Inhibitors & In Silico Phenotypic Analysis.** *PloS one*  
Rath, B. A., Yousef, K. P., Katzenstein, D. K., Shafer, R. W., Schütte, C., von Kleist, M., Merigan, T. C.  
2013; 8 (4)
  - **Prototypical Recombinant Multi-Protease Inhibitor Resistant Infectious Molecular Clones of Human Immunodeficiency Virus Type-1.** *Antimicrobial agents and chemotherapy*  
Varghese, V., Mitsuya, Y., Fessel, W. J., Liu, T. F., Melikian, G. L., Katzenstein, D. A., Schiffer, C. A., Holmes, S. P., Shafer, R. W.  
2013
  - **HIV-1 Amino Acid Changes Among Participants With Virologic Failure: Associations With First-line Efavirenz or Atazanavir Plus Ritonavir and Disease Status** *JOURNAL OF INFECTIOUS DISEASES*  
Mollan, K., Daar, E. S., Sax, P. E., Balamane, M., Collier, A. C., Fischl, M. A., Lalama, C. M., Bosch, R. J., Tierney, C., Katzenstein, D.  
2012; 206 (12): 1920-1930
  - **Are subtype differences important in HIV drug resistance?** *CURRENT OPINION IN VIROLOGY*  
Lessells, R. J., Katzenstein, D. K., de Oliveira, T.  
2012; 2 (5): 636-643
  - **Panel of Prototypical Recombinant Infectious Molecular Clones Resistant to Nevirapine, Efavirenz, Etravirine, and Rilpivirine** *ANTIMICROBIAL AGENTS AND CHEMOTHERAPY*  
Balamane, M., Varghese, V., Melikian, G. L., Fessel, W. J., Katzenstein, D. A., Shafer, R. W.  
2012; 56 (8): 4522-4524
  - **Lopinavir/ritonavir monotherapy after virologic failure of first-line antiretroviral therapy in resource-limited settings** *AIDS*  
Bartlett, J. A., Ribaldo, H. J., Wallis, C. L., Aga, E., Katzenstein, D. A., Stevens, W. S., Norton, M. R., Klingman, K. L., Hosseinipour, M. C., Crump, J. A., Supparatpinyo, K., Badal-Faesen, S., Kallungal, et al  
2012; 26 (11): 1345-1353
  - **Primary Drug Resistance in South Africa: Data from 10 Years of Surveys** *AIDS RESEARCH AND HUMAN RETROVIRUSES*  
Manasa, J., Katzenstein, D., Cassol, S., Newell, M., de Oliveira, T.  
2012; 28 (6): 558-565
  - **Global analysis of sequence diversity within HIV-1 subtypes across geographic regions** *FUTURE VIROLOGY*  
Huang, A., Hogan, J. W., Istrail, S., DeLong, A., Katzenstein, D. A., Kantor, R.  
2012; 7 (5): 505-517
  - **Viremia and HIV-1 Drug Resistance Mutations Among Patients Receiving Second-Line Highly Active Antiretroviral Therapy in Chennai, Southern India** *CLINICAL INFECTIOUS DISEASES*  
Saravanan, S., Vidy, M., Balakrishnan, P., Kantor, R., Solomon, S. S., Katzenstein, D., Kumarasamy, N., Yeptomi, T., Sivamalar, S., Rifkin, S., Mayer, K. H., Solomon, S.  
2012; 54 (7): 995-1000
  - **Zidovudine (AZT) Monotherapy Selects for the A360V Mutation in the Connection Domain of HIV-1 Reverse Transcriptase** *PLOS ONE*  
Brehm, J. H., Scott, Y., Koontz, D. L., Perry, S., Hammer, S., Katzenstein, D., Mellors, J. W., Sluis-Cremer, N.  
2012; 7 (2)
  - **Reverse Transcriptase Substitution at Codons 208 and 228 Among Treatment-Experienced HIV-1 Subtype-C-Infected Indian Patients Is Strongly Associated With Thymidine Analogue Mutations** *JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES*

- Saravanan, S., Madhavan, V., Solomon, S. S., Kantor, R., Katzenstein, D., Sivamalar, S., Kumarasamy, N., Smith, D. M., Mayer, K. H., Solomon, S., Balakrishnan, P.  
2012; 59 (2): E26-E27
- **Comparing Peripheral Blood Mononuclear Cell DNA and Circulating Plasma viral RNA pol Genotypes of Subtype C HIV-1.** *Journal of AIDS & clinical research*  
Banks, L., Gholamin, S., White, E., Zijenah, L., Katzenstein, D. A.  
2012; 3 (2): 141-147
  - **HIV disclosure patterns, predictors, and psychosocial correlates among HIV positive women in Zimbabwe** *AIDS CARE-PSYCHOLOGICAL AND SOCIO-MEDICAL ASPECTS OF AIDS/HIV*  
Patel, R., Ratner, J., Gore-Felton, C., Kadzirange, G., Woelk, G., Katzenstein, D.  
2012; 24 (3): 358-368
  - **Abacavir/Lamivudine Versus Tenofovir DF/Emtricitabine as Part of Combination Regimens for Initial Treatment of HIV: Final Results** *JOURNAL OF INFECTIOUS DISEASES*  
Sax, P. E., Tierney, C., Collier, A. C., Daar, E. S., Mollan, K., Budhathoki, C., Godfrey, C., Jahed, N. C., Myers, L., Katzenstein, D., Farajallah, A., Rooney, J. F., Ha, et al  
2011; 204 (8): 1191-1201
  - **Placental Malaria and Mother-to-Child Transmission of Human Immunodeficiency Virus-1 in Rural Rwanda** *AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE*  
Bulterys, P. L., Chao, A., Dalai, S. C., Zink, M. C., Dushimimana, A., Katzenstein, D., Saah, A. J., Bulterys, M.  
2011; 85 (2): 202-206
  - **Surveillance of Transmitted Antiretroviral Drug Resistance among HIV-1 Infected Women Attending Antenatal Clinics in Chitungwiza, Zimbabwe** *PLOS ONE*  
Tshabalala, M., Manasa, J., Zijenah, L. S., Rusakaniko, S., Kadzirange, G., Muccheche, M., Kassaye, S., Johnston, E., Katzenstein, D.  
2011; 6 (6)
  - **The Incidence and Correlates of Symptomatic and Asymptomatic Chlamydia trachomatis and Neisseria gonorrhoeae Infections in Selected Populations in Five Countries** *SEXUALLY TRANSMITTED DISEASES*  
Detels, R., Green, A. M., Klausner, J. D., Katzenstein, D., Gaydos, C., Handsfield, H. H., Pequegnat, W., Mayer, K., Hartwell, T. D., Quinn, T. C.  
2011; 38 (6): 503-509
  - **Atazanavir Plus Ritonavir or Efavirenz as Part of a 3-Drug Regimen for Initial Treatment of HIV-1** *ANNALS OF INTERNAL MEDICINE*  
Daar, E. S., Tierney, C., Fischl, M. A., Sax, P. E., Mollan, K., Budhathoki, C., Godfrey, C., Jahed, N. C., Myers, L., Katzenstein, D., Farajallah, A., Rooney, J. F., Pappa, et al  
2011; 154 (7)
  - **Adherence to Drug-Refill Is a Useful Early Warning Indicator of Virologic and Immunologic Failure among HIV Patients on First-Line ART in South Africa** *PLOS ONE*  
El-Khatib, Z., Katzenstein, D., Marrone, G., Laher, F., Mohapi, L., Petzold, M., Morris, L., Ekstrom, A. M.  
2011; 6 (3)
  - **Lower CD4 Cell Count and Higher Virus Load, but Not Antiretroviral Drug Resistance, Are Associated with AIDS-Defining Events and Mortality: An ACTG Longitudinal Linked Randomized Trials (ALLRT) Analysis** *HIV CLINICAL TRIALS*  
Swindells, S., Jiang, H., Mukherjee, A. L., Winters, M., Bosch, R. J., Katzenstein, D.  
2011; 12 (2): 79-88
  - **Adherence and virologic suppression during the first 24 weeks on antiretroviral therapy among women in Johannesburg, South Africa - a prospective cohort study** *BMC PUBLIC HEALTH*  
El-Khatib, Z., Ekstrom, A. M., Coovadia, A., Abrams, E. J., Petzold, M., Katzenstein, D., Morris, L., Kuhn, L.  
2011; 11
  - **Operational challenges in delivering CD4 diagnostics in sub-Saharan Africa** *AIDS CARE-PSYCHOLOGICAL AND SOCIO-MEDICAL ASPECTS OF AIDS/HIV*  
Thairu, L., KATZENSTEIN, D., Israelski, D.  
2011; 23 (7): 814-821
  - **Drug resistance and tropism both are associated with AIDS-defining clinical events among nucleoside-treated subjects in ACTG175** *20th International Workshop on HIV and Hepatitis Virus Drug Resistance and Curative Strategies*



- Gholamin, S., Shin, H., Huang, H., White, E., Shulman, N., KATZENSTEIN, D.  
INT MEDICAL PRESS LTD.2011: A58–A58
- **Reverse transcriptase (RT) and protease (PR) drug resistance mutations (DRM) and evolution at virological failure (VF) in AIDS Clinical Trials Group (ACTG) study A5202** *20th International Workshop on HIV and Hepatitis Virus Drug Resistance and Curative Strategies*  
Mollan, K. R., Daar, E. S., Tierney, C., Dalai, S., BALAMANE, M., Sax, P. E., Collier, A. C., Fischl, M. A., Lalama, C. M., Bosch, R. J., KATZENSTEIN, D.  
INT MEDICAL PRESS LTD.2011: A124–A124
  - **Viral Sequence Analysis from HIV-Infected Mothers and Infants: Molecular Evolution, Diversity, and Risk Factors for Mother-To-Child Transmission** *CLINICS IN PERINATOLOGY*  
Bulterys, P. L., Dalai, S. C., Katzenstein, D. A.  
2010; 37 (4): 739-?
  - **Genetic Analyses of HIV-1 env Sequences Demonstrate Limited Compartmentalization in Breast Milk and Suggest Viral Replication within the Breast That Increases with Mastitis** *JOURNAL OF VIROLOGY*  
Gantt, S., Carlsson, J., Heath, L., Bull, M. E., Shetty, A. K., Mutsvangwa, J., Musingwini, G., Woelk, G., Zijenah, L. S., Katzenstein, D. A., Mullins, J. I., Frenkel, L. M.  
2010; 84 (20): 10812-10819
  - **Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa** *AIDS*  
El-Khatib, Z., Ekstrom, A. M., Ledwaba, J., Mohapi, L., Laher, F., Karstaedt, A., Charalambous, S., Petzold, M., Katzenstein, D., Morris, L.  
2010; 24 (11): 1679-1687
  - **Nucleic Acid Template and the Risk of a PCR-Induced HIV-1 Drug Resistance Mutation** *PLOS ONE*  
Varghese, V., Wang, E., Babrzadeh, F., Bachmann, M. H., Shahriar, R., Liu, T., Mappala, S. J., Gharizadeh, B., Fessel, W. J., Katzenstein, D., Kassaye, S., Shafer, R. W.  
2010; 5 (6)
  - **Fertility desires and condom use among HIV-positive women at an antiretroviral roll-out program in Zimbabwe.** *African journal of reproductive health*  
McClellan, M. K., Patel, R., Kadzirange, G., Chipatod, T., Katzenstein, D.  
2010; 14 (2): 27-35
  - **Unusual five amino acid insert within subtype C HIV-1 envelope contributes to dual-tropism (X4R5)** *AIDS*  
White, E. J., McColgan, B., Kassaye, S., Zijenah, L., Katzenstein, D.  
2010; 24 (7): 1063-1064
  - **A Controlled Trial of Initial Antiviral Regimens for HIV-1 Infection** *NEW ENGLAND JOURNAL OF MEDICINE*  
Parienti, J.  
2010; 362 (9): 854-854
  - **Detection of HIV-1 in Saliva: Implications for Case-Identification, Clinical Monitoring and Surveillance for Drug Resistance.** *The open virology journal*  
Balamane, M., Winters, M. A., Dalai, S. C., Freeman, A. H., Traves, M. W., Israelski, D. M., Katzenstein, D. A., Klausner, J. D.  
2010; 4: 88-93
  - **Abacavir-Lamivudine versus Tenofovir-Emtricitabine for Initial HIV-1 Therapy** *NEW ENGLAND JOURNAL OF MEDICINE*  
Sax, P. E., Tierney, C., Collier, A. C., Fischl, M. A., Mollan, K., Peeples, L., Godfrey, C., Jahed, N. C., Myers, L., Katzenstein, D., Farajallah, A., Rooney, J. F., Ha, et al  
2009; 361 (23): 2230-2240
  - **Evolution and molecular epidemiology of subtype C HIV-1 in Zimbabwe** *AIDS*  
Dalai, S. C., de Oliveira, T., Harkins, G. W., Kassaye, S. G., Lint, J., Manasa, J., Johnston, E., Katzenstein, D.  
2009; 23 (18): 2523-2532
  - **Expanding Antiretroviral Options in Resource-Limited Settings-A Cost-Effectiveness Analysis** *JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES*  
Bendavid, E., Wood, R., Katzenstein, D. A., Bayoumi, A. M., Owens, D. K.  
2009; 52 (1): 106-113
  - **TREAT Asia Quality Assessment Scheme (TAQAS) to standardize the outcome of HIV genotypic resistance testing in a group of Asian laboratories** *JOURNAL OF VIROLOGICAL METHODS*  
Land, S., Cunningham, P., Zhou, J., Frost, K., Katzenstein, D., Kantor, R., Chen, Y. A., Oka, S., DeLong, A., Sayer, D., Smith, J., Dax, E. M., Law, et al



2009; 159 (2): 185-193

- **Evaluation of two human immunodeficiency virus-1 genotyping systems: ViroSeq (TM) 2.0 and an in-house method** *JOURNAL OF VIROLOGICAL METHODS*  
Saravanan, S., Vidya, M., Balakrishnan, P., Kumarasamy, N., Solomon, S. S., Solomon, S., Kantor, R., Katzenstein, D., Ramratnam, B., Mayer, K. H.  
2009; 159 (2): 211-216
- **Lack of Evidence for Frequent Heterosexual Transmission of Human Herpesvirus 8 in Zimbabwe** *16th International AIDS Conference*  
Campbell, T. B., Borok, M., Ndemera, B., Fiorillo, S., White, I. E., Zhang, X., Machezano, R. N., Katzenstein, D., Gwanzura, L.  
UNIV CHICAGO PRESS.2009: 1601-8
- **CCR5-and CXCR4-Tropic Subtype C Human Immunodeficiency Virus Type 1 Isolates Have a Lower Level of Pathogenic Fitness than Other Dominant Group M Subtypes: Implications for the Epidemic** *JOURNAL OF VIROLOGY*  
Abraha, A., Nankya, I. L., Gibson, R., Demers, K., Tebit, D. M., Johnston, E., Katzenstein, D., Siddiqui, A., Herrera, C., Fischetti, L., Shattock, R. J., Arts, E. J.  
2009; 83 (11): 5592-5605
- **Envelope Coreceptor Tropism, Drug Resistance, and Viral Evolution Among Subtype C HIV-1-Infected Individuals Receiving Nonsuppressive Antiretroviral Therapy** *29th Annual Meeting of the Society-of-Behavioral-Medicine*  
Kassaye, S., Johnston, E., McColgan, B., Kantor, R., Enah, L. Z., Katzenstein, D.  
LIPPINCOTT WILLIAMS & WILKINS.2009: 9-18
- **Genotypic HIV type-1 drug resistance among patients with immunological failure to first-line antiretroviral therapy in south India** *ANTIVIRAL THERAPY*  
Vidya, M., Saravanan, S., Uma, S., Kumarasamy, N., Sunil, S. S., Kantor, R., Katzenstein, D., Ramratnam, B., Mayer, K. H., Suniti, S., Balakrishnan, P.  
2009; 14 (7): 1005-1009
- **Quality of life, psychosocial health, and antiretroviral therapy among HIV-positive women in Zimbabwe** *AIDS CARE-PSYCHOLOGICAL AND SOCIO-MEDICAL ASPECTS OF AIDS/HIV*  
Patel, R., Kassaye, S., Gore-Felton, C., Wyshak, G., Kadzirange, G., Woelk, G., Katzenstein, D.  
2009; 21 (12): 1517-1527
- **Alanine aminotransferase levels are not significantly elevated in patients with HIV/HBV co-infection and lamivudine resistance** *INTERNATIONAL JOURNAL OF STD & AIDS*  
Bhattacharya, D., KATZENSTEIN, D., Wong, A., Israelski, D., Imperial, J. C., Keeffe, E. B., DONOVAN, R. M.  
2008; 19 (11): 780-781
- **Bayesian network analyses of resistance pathways against efavirenz and nevirapine** *AIDS*  
Deforche, K., Camacho, R. J., Grossman, Z., Soares, M. A., Van Laethem, K., Katzenstein, D. A., Harrigan, P. R., Kantor, R., Shafer, R., Vandamme, A.  
2008; 22 (16): 2107-2115
- **Cost-effectiveness of HIV monitoring strategies in resource-limited settings - A Southern African analysis** *ARCHIVES OF INTERNAL MEDICINE*  
Bendavid, E., Young, S. D., Katzenstein, D. A., Bayoumi, A. M., Sanders, G. D., Owens, D. K.  
2008; 168 (17): 1910-1918
- **Cytomegalovirus and Epstein-Barr virus in breast milk are associated with HIV-1 shedding but not with mastitis** *13th Conference on Retroviruses and Opportunistic Infections*  
Gantt, S., Carlsson, J., Shetty, A. K., Seidel, K. D., Qin, X., Mutsvangwa, J., Musingwini, G., Woelk, G., Zijenah, L. S., Katzenstein, D. A., Frenkel, L. M.  
LIPPINCOTT WILLIAMS & WILKINS.2008: 1453-60
- **Genotypic susceptibility scores and HIV type 1 RNA responses in treatment-experienced subjects with HIV type 1 infection** *AIDS RESEARCH AND HUMAN RETROVIRUSES*  
Anderson, J. A., Jiang, H., Ding, X., Petch, L., Journigan, T., Fiscus, S. A., Haubrich, R., Katzenstein, D., Swanstrom, R., Gulick, R. M.  
2008; 24 (5): 685-694
- **Metabolic and Immune Activation Effects of Treatment Interruption in Chronic HIV-1 Infection: Implications for Cardiovascular Risk** *PLOS ONE*  
Tebas, P., Henry, W. K., Matining, R., Weng-Cherng, D., Schmitz, J., Valdez, H., Jahed, N., Myers, L., Powderly, W. G., Katzenstein, D.  
2008; 3 (4)
- **A multicenter trial of selegiline transdermal system for HIV-associated cognitive impairment** *NEUROLOGY*  
Schifitto, G., Zhang, J., Evans, S. R., Sacktor, N., Simpson, D., Millar, L. L., HUNG, V. L., Miller, E. N., Smith, E., Ellis, R. J., Valcour, V., Singer, E., Marra, et al  
2007; 69 (13): 1314-1321

- **Laboratory indicators of mastitis are not associated with elevated HIV-1 DNA loads or predictive of HIV-1 RNA loads in breast milk** *13th Conference on Retroviruses and Opportunistic Infections*  
Gantt, S., Shetty, A. K., Seidel, K. D., Matasa, K., Musingwini, G., Woelk, G., Zijenah, L. S., Katzenstein, D. A., Frenkel, L. M.  
OXFORD UNIV PRESS INC.2007: 570-76
- **Drug resistance in plasma and breast milk after single-dose nevirapine in subtype C HIV type 1: Population and clonal sequence analysis** *AIDS RESEARCH AND HUMAN RETROVIRUSES*  
Kassaye, S., Lee, E., Kantor, R., Johnston, E., Winters, M., Zijenah, L., Mateta, P., Katzenstein, D.  
2007; 23 (8): 1055-1061
- **More on the treatment-tropism relationship: The impact of prior antiretroviral treatment on HIV coreceptor tropism among subjects entering AIDS clinical trials group 175** *JOURNAL OF INFECTIOUS DISEASES*  
Shulman, N. S., Kassaye, S. G., Winters, M. A., Johnston, E., Katzenstein, D. A.  
2007; 196 (2): 328-329
- **Bayesian network analysis of resistance pathways against HIV-1 protease inhibitors** *11th International Workshop on Virus Evolution and Molecular Epidemiology*  
Deforche, K., Camacho, R., Grossman, Z., Silander, T., Soares, M. A., Moreau, Y., Shafer, R. W., Van Laethem, K., CARVALHO, A. P., Wynhoven, B., Cane, P., Snoeck, J., Clarke, et al  
ELSEVIER SCIENCE BV.2007: 382-90
- **Non-nucleoside phenotypic hypersusceptibility cut-point determination from ACTG 359** *HIV CLINICAL TRIALS*  
Haubrich, R. H., Jiang, H., Swanstrom, R., Bates, M., Katzenstein, D., Petch, L., Fletcher, C. V., Fiscus, S. A., Gulick, R. M.  
2007; 8 (2): 63-67
- **Factors in the delayed HIV presentation of immigrants in Northern California: implications for voluntary counseling and testing programs.** *Journal of immigrant and minority health*  
Levy, V., Prentiss, D., Balmas, G., Chen, S., Israelski, D., Katzenstein, D., Page-Shafer, K.  
2007; 9 (1): 49-54
- **Genetic distance of rebound viraemia from proviral DNA and the selection of drug-resistance mutations in HIV-1 RNA after treatment interruption** *16th International HIV Drug Resistance Workshop*  
Dalai, S., Winters, M., Kassaye, S., KATZENSTEIN, D.  
INT MEDICAL PRESS LTD.2007: S108-S108
- **Perceived risks and benefits of HIV testing, and predictors of acceptance of HIV counselling and testing among pregnant women in Zimbabwe** *INTERNATIONAL JOURNAL OF STD & AIDS*  
Martin-Herz, S. P., Shetty, A. K., Bassett, M. T., Ley, C., Mhazo, M., Moyo, S., Herz, A. M., Katzenstein, D.  
2006; 17 (12): 835-841
- **Diversity, drug resistance, and the epidemic of subtype CHIV-1 in Africa** *Symposium on Bridging Generations Toward an Understanding of Infectious Disease Pathogenesis*  
Katzenstein, D.  
UNIV CHICAGO PRESS.2006: S45-S50
- **Treatment for adult HIV infection - 2006 recommendations of the International AIDS Society-USA panel** *JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION*  
Hammer, S. M., Saag, M. S., Schechter, M., Montaner, J. S., Schooley, R. T., Jacobsen, D. M., Thompson, M. A., Carpenter, C. C., Fischl, M. A., Gazzard, B. G., Gatell, J. M., Hirsch, M. S., Katzenstein, et al  
2006; 296 (7): 827-843
- **Affordable flow cytometry for enumeration of absolute CD4(+) T-lymphocytes to identify subtype CHIV-1 infected adults requiring antiretroviral therapy (ART) and monitoring response to ART in a resource-limited setting** *JOURNAL OF TRANSLATIONAL MEDICINE*  
Zijenah, L. S., Kadzirange, G., Madzime, S., Borok, M., Mudiwa, C., Tobaiwa, O., Muccheche, M., Rusakaniko, S., Katzenstein, D. A.  
2006; 4
- **A pilot study evaluating time to CD4 T-cell count < 350 cells/mm(3) after treatment interruption following antiretroviral therapy +/- interleukin 2: Results of ACTG A5102** *JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES*  
Henry, K., Katzenstein, D., Cherng, D. W., Valdez, H., Powderly, W., Vargas, M. B., Jahed, N. C., Jacobson, J. M., Myers, L. S., Schmitz, J. L., Winters, M., Tebas, P.  
2006; 42 (2): 140-148

- **Of molecules, macaques and global AIDS** *AIDS*  
Katzenstein, D. A.  
2006; 20 (7): 1065-1066
- **HIV-1 pol mutation frequency by subtype and treatment experience: extension of the HIVseq program to seven non-B subtypes** *AIDS*  
Rhee, S. Y., Kantor, R., Katzenstein, D. A., Camacho, R., Morris, L., Sirivichayakul, S., Jorgensen, L., Brigido, L. F., Schapiro, J. M., Shafer, R. W.  
2006; 20 (5): 643-651
- **Discordances between interpretation algorithms for genotypic resistance to protease and reverse transcriptase inhibitors of human immunodeficiency virus are subtype dependent** *ANTIMICROBIAL AGENTS AND CHEMOTHERAPY*  
Snoeck, J., Kantor, R., Shafer, R. W., Van Laethem, K., Deforche, K., CARVALHO, A. P., Wynhoven, B., Soares, M. A., Cane, P., Clarke, J., Pillay, C., Sirivichayakul, S., Ariyoshi, et al  
2006; 50 (2): 694-701
- **A pilot study to assess the immunologic and virologic efficacy of generic nevirapine, zidovudine and lamivudine in the treatment of HIV-1 infected women with pre-exposure to single dose nevirapine or short course zidovudine and their spouses in Chitungwiza, Zimbabwe.** *Central African journal of medicine*  
Zijenah, L. S., Kadzirange, G., Rusakaniko, S., KUFA, T., Gonah, N., Tobaiwa, O., Gwanzura, C., Matsikire, E., Katzenstein, D. A.  
2006; 52 (1-2): 1-8
- **The feasibility of voluntary counselling and HIV testing for pregnant women using community volunteers in Zimbabwe** *14th International AIDS Conference*  
Shetty, A. K., Mhazo, M., Moyo, S., Von Lieven, A., Mateta, P., Katzenstein, D. A., Maldonado, Y., Hill, D., Bassett, M. T.  
ROYAL SOC MEDICINE PRESS LTD.2005: 755-59
- **Breast-milk shedding of drug-resistant HIV-1 subtype C in women exposed to single-dose nevirapine** *11th Conference on Retroviruses and Opportunistic Infections*  
Lee, E. J., Kantor, R., Zijenah, L., Sheldon, W., Emel, L., Mateta, P., Johnston, E., Wells, J., Shetty, A. K., Coovadia, H., Maldonado, Y., Jones, S. A., Mofenson, et al  
UNIV CHICAGO PRESS.2005: 1260-64
- **Signal-boosted qualitative ultrasensitive p24 antigen assay for diagnosis of subtype CHIV-1 infection in infants under the age of 2 years** *JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES*  
Zijenah, L. S., Tobaiwa, O., Rusakaniko, S., Nathoo, K. J., Nhembe, M., Matibe, P., Katzenstein, D. A.  
2005; 39 (4): 391-394
- **Nonnucleoside reverse transcriptase inhibitor phenotypic hypersusceptibility can be demonstrated in different assays** *12th International HIV Drug Resistance Workshop*  
Shulman, N. S., Delgado, D., Bosch, R. J., Winters, M. A., Johnston, E., Shafer, R. W., Katzenstein, D. A., Merigan, T. C.  
LIPPINCOTT WILLIAMS & WILKINS.2005: 78-81
- **Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration** *PLOS MEDICINE*  
Kantor, R., Katzenstein, D. A., Efron, B., CARVALHO, A. P., Wynhoven, B., Cane, P., Clarke, J., Sirivichayakul, S., Soares, M. A., Snoeck, J., Pillay, C., Rudich, H., Rodrigues, et al  
2005; 2 (4): 325-337
- **Viral dynamics and CD4(+) T cell counts in subtype C human immunodeficiency virus type 1-infected individuals from southern Africa** *AIDS RESEARCH AND HUMAN RETROVIRUSES*  
Gray, C. M., Williamson, C., Bredell, H., Puren, A., Xia, X. H., Filter, R., Zijenah, L., Cao, H. Y., Morris, L., Vardas, E., Colvin, M., Gray, G., McIntyre, et al  
2005; 21 (4): 285-291
- **HIV type 1 genotypic variation in an antiretroviral treatment-naive population in southern India** *AIDS RESEARCH AND HUMAN RETROVIRUSES*  
Balakrishnan, P., Kumarasamy, N., Kantor, R., Solomon, S., Vidya, S., MAYER, K. H., Newstein, M., Thyagarajan, S. P., KATZENSTEIN, D., Ramratnam, B.  
2005; 21 (4): 301-305
- **T lymphocytes among HIV-infected and -uninfected infants: CD4/CD8 ratio as a potential tool in diagnosis of infection in infants under the age of 2 years** *JOURNAL OF TRANSLATIONAL MEDICINE*  
Zijenah, L. S., Katzenstein, D. A., Nathoo, K. J., Rusakaniko, S., Tobaiwa, O., Gwanzura, C., Bikoue, A., Nhembe, M., Matibe, P., Janossy, G.  
2005; 3
- **Mapping nevirapine and efavirenz resistance using Bayesian networks of HIV-1 pol sequences of subtypes A, B, C, F and G** *14th International HIV Drug Resistance Workshop*

- Deforche, K., Camacho, R., Grossman, Z., Silander, T., Soares, M. A., Shafer, R. W., Van Laethem, K., CARVALHO, A. P., Wynhoven, B., Cane, P., Clarke, J., Snoeck, J., Sirivichayakul, et al  
INT MEDICAL PRESS LTD.2005: S132-S132
- **Selection of resistance following first-line anti-retroviral regimens among HIV-1 subtypes** *14th International HIV Drug Resistance Workshop*  
Kantor, R., DeLong, A., Shafer, R. W., CARVALHO, A. P., Wynhoven, B., Cane, P., Sirivichayakul, S., Soares, M. A., Snoeck, J., Rudich, H., Rodrigues, R., Holguin, A., Ariyoshi, et al  
INT MEDICAL PRESS LTD.2005: S146-S146
  - **Interactions between nevirapine resistance mutations and NRTI resistance mutations** *14th International HIV Drug Resistance Workshop*  
Deforche, K., Camacho, R., Grossman, Z., Silander, T., Soares, M. A., Shafer, R. W., Van Laethem, K., CARVALHO, A. P., Wynhoven, B., Cane, P., Clarke, J., Snoeck, J., Sirivichayakul, et al  
INT MEDICAL PRESS LTD.2005: S144-S144
  - **Novel and promiscuous CTL epitopes in conserved regions of Gag targeted by individuals with early subtype CHIV type infection from southern Africa** *JOURNAL OF IMMUNOLOGY*  
Masemola, A. M., Mashishi, T. N., Khoury, G., Bredell, H., Paximadis, M., Mathebula, T., Barkhan, D., Puren, A., Vardas, E., Colvin, M., Zijenah, L., KATZENSTEIN, D., Musonda, et al  
2004; 173 (7): 4607-4617
  - **Genetic correlates of efavirenz hypersusceptibility** *11th Conference on Retroviruses and Opportunistic Infections*  
Shulman, N. S., Bosch, R. J., Mellors, J. W., Albrecht, M. A., Katzenstein, D. A.  
LIPPINCOTT WILLIAMS & WILKINS.2004: 1781-85
  - **Weighted phenotypic susceptibility scores are predictive of the HIV-1 RNA response in protease inhibitor-experienced HIV-1-infected subjects** *9th Conference on Retroviruses and Opportunistic Infections*  
Swanstrom, R., Bosch, R. J., KATZENSTEIN, D., Cheng, H. L., Jiang, H. Y., Hellmann, N., Haubrich, R., Fiscus, S. A., Fletcher, C. V., Acosta, E. P., Gulick, R. M.  
UNIV CHICAGO PRESS.2004: 886-93
  - **Discordances between interpretation algorithms for genotypic resistance to protease and reverse transcriptase inhibitors are subtype dependent** *13th International HIV Drug Resistance Workshop*  
Snoeck, J., Kantor, R., Shafer, R. W., Van Laethem, K., Deforche, K., CARVALHO, A. P., Wynhoven, B., Soares, M. A., Cane, P., Clarke, J., Pillay, C., Sirivichayakul, S., Ariyoshi, et al  
INT MEDICAL PRESS LTD.2004: U91-U92
  - **Genotypic predictors of a response to didanosine monotherapy in zidovudine-experienced patients** *13th International HIV Drug Resistance Workshop*  
Delgado, J., Hughes, M., Winters, M. A., Smith, K., Merigan, T. C., Katzenstein, D. A., Shulman, N. S.  
INT MEDICAL PRESS LTD.2004: U95-U95
  - **d4T virtual phenotype can predict virological response to d4T monotherapy after AZT treatment, but not at the current cutoff** *13th International HIV Drug Resistance Workshop*  
Shulman, N. S., Hughes, M., Winters, M. A., Delgado, J., Merigan, T. C., Katzenstein, D. A.  
INT MEDICAL PRESS LTD.2004: U94-U95
  - **Evolution of resistance to drugs in HIV-1-infected patients failing antiretroviral therapy** *AIDS*  
Kantor, R., Shafer, R. W., Follansbee, S., Taylor, J., Shilane, D., Hurley, L., Nguyen, D. P., KATZENSTEIN, D., Fessel, W. J.  
2004; 18 (11): 1503-1511
  - **Treatment for adult HIV infection - 2004 recommendations of the International AIDS Society-USA panel** *JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION*  
Yeni, P. G., Hammer, S. M., Hirsch, M. S., Saag, M. S., Schechter, M., Carpenter, C. C., Fischl, M. A., Gatell, J. M., Gazzard, B. G., Jacobsen, D. M., Katzenstein, D. A., Montaner, J. S., Richman, et al  
2004; 292 (2): 251-265
  - **Hierarchical targeting of subtype C human immunodeficiency virus type 1 proteins by CD8(+) T cells: Correlation with viral load** *JOURNAL OF VIROLOGY*  
Masemola, A., Mashishi, T., Khoury, G., Mohube, P., Mokgotho, P., Vardas, E., Colvin, M., Zijenah, L., KATZENSTEIN, D., Musonda, R., Allen, S., Kumwenda, N., Taha, et al  
2004; 78 (7): 3233-3243

- **Sex-based differences in saquinavir pharmacology and virologic response in AIDS Clinical Trials Group study 359** *2nd International-AIDS-Society Conference on HIV Pathogenesis and Treatment*  
Fletcher, C. V., Jiang, H. Y., Brundage, R. C., Acosta, E. P., Haubrich, R., KATZENSTEIN, D., Gulick, R. M.  
OXFORD UNIV PRESS INC.2004: 1176–84
- **The longer the better? Four years of durable, initially boosted protease treatment.** *AIDS*  
Katzenstein, D.  
2004; 18 (5): 811-813
- **Mycobacterium tuberculosis/HIV-1 coinfection and disease: Role of human leukocyte antigen variation** *13th International Congress of Histocompatibility and Immunogenetics*  
Louie, L. G., Hartogensis, W. E., Jackman, R. P., Schultz, K. A., Zijenah, L. S., Yiu, C. H., Nguyen, V. D., Sohsman, M. Y., Katzenstein, D. K., Mason, P. R.  
UNIV CHICAGO PRESS.2004: 1084–90
- **Drug resistance in non-subtype BHIV-1** *JOURNAL OF CLINICAL VIROLOGY*  
Kantor, R., KATZENSTEIN, D.  
2004; 29 (3): 152-159
- **Infant feeding practices of HIV-infected and uninfected women in Zimbabwe** *13th International AIDS Conference*  
GOTTLIEB, D., Shetty, A. K., Mapfungautsi, R. M., Bassett, M. T., Maldonado, Y., Katzenstein, D. A.  
MARY ANN LIEBERT INC.2004: 45–53
- **Safety and Trough Concentrations of Nevirapine Prophylaxis Given Daily, Twice Weekly, or Weekly in Breast-Feeding Infants From Birth to 6 Months** *JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES*  
Shetty, A. K., Coovadia, H. M., Mirochnick, M. M., Maldonado, Y., Mofenson, L. M., Eshleman, S. H., Fleming, T., Emel, L., George, K., Katzenstein, D. A., Wells, J., Maponga, C. C., Mwatha, et al  
2003; 34 (5): 482-490
- **Evaluation of cutpoints for phenotypic hypersusceptibility to efavirenz** *AIDS*  
Bosch, R. J., Downey, G. F., Katzenstein, D. A., Hellmann, N., Bacheler, L., Albrecht, M. A.  
2003; 17 (16): 2395-2396
- **HIV/AIDS care and treatment in sub-Saharan Africa.** *AIDS reviews*  
Kassaye, S. G., Katzenstein, D.  
2003; 5 (4): 195-204
- **Assessing resistance costs of antiretroviral therapies via measures of future drug options** *11th International Workshop on HIV Drug Resistance and Treatment Strategies*  
Jiang, H. Y., Deeks, S. G., Kuritzkes, D. R., Lallemand, M., KATZENSTEIN, D., Albrecht, M., DeGruttola, V.  
OXFORD UNIV PRESS INC.2003: 1001–8
- **Genotype, phenotype, and virtual phenotype: who needs what and why?** *Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002)*  
Katzenstein, D. A.  
2003; 2 (4): 140-146
- **Clinical impact of the M184V mutation on switching to didanosine or maintaining lamivudine treatment in nucleoside reverse-transcriptase inhibitor-experienced patients** *11th International Workshop on HIV Drug Resistance and Treatment Strategies*  
Winters, M. A., Bosch, R. J., Albrecht, M. A., Katzenstein, D. A.  
UNIV CHICAGO PRESS.2003: 537–40
- **High frequency of syncytium-inducing and CXCR4-tropic viruses among human immunodeficiency virus type 1 subtype C-infected patients receiving antiretroviral treatment** *JOURNAL OF VIROLOGY*  
Johnston, E. R., Zijenah, L. S., Mutetwa, S., Kantor, R., Kittinunvorakoon, C., Katzenstein, D. A.  
2003; 77 (13): 7682-7688
- **The evaluation of the HIV/AIDS Drug Access Initiatives in Cote D'Ivoire, Senegal and Uganda: how access to antiretroviral treatment can become feasible in Africa** *AIDS*  
KATZENSTEIN, D., Laga, M., Moatti, J. P.  
2003; 17: S1-S4

- **Non-nucleoside reverse transcriptase inhibitor hypersusceptibility can be demonstrated in multicycle phenotype assays and in inhibition assays of purified HIV-1 reverse transcriptases** *12th International HIV Drug Resistance Workshop*  
Shulman, N. S., Delgado, J., Winters, M. A., Johnston, E., Katzenstein, D. A., Shafer, R. W., Merigan, T.  
INT MEDICAL PRESS LTD.2003: U50-U51
- **Rapid flux in non-nucleoside reverse transcriptase inhibitor resistance mutations among subtype CHIV-1-infected women after single dose nevirapine** *12th International HIV Drug Resistance Workshop*  
Kantor, R., Lee, E., Johnston, E., Mateta, P., Zijenah, L., Maldonado, Y., KATZENSTEIN, D.  
INT MEDICAL PRESS LTD.2003: U78-U79
- **Nucleic acid differences between HIV-1 non-B and B reverse transcriptase and protease sequences at drug resistance positions** *12th International HIV Drug Resistance Workshop*  
Kantor, R., CARVALHO, A. P., Wynhoven, B., Soares, M. A., Cane, P., Clarke, J., Snoeck, J., Pillay, C., Sirivichayakul, S., Ariyoshi, K., Holguin, A., Rudich, H., Rodrigues, et al  
INT MEDICAL PRESS LTD.2003: U58-U59
- **Comparison of five interpretation algorithms for the prediction of protease inhibitor susceptibility in HIV-1 non-B subtypes** *12th International HIV Drug Resistance Workshop*  
Snoeck, J., Kantor, R., Shafer, R. W., Derdelinckx, I., CARVALHO, A. P., Wynhoven, B., Soares, M. A., Cane, P., Clarke, J., Pillay, C., Sirivichayakul, S., Ariyoshi, K., Holguin, et al  
INT MEDICAL PRESS LTD.2003: U98-U99
- **Phenotypic susceptibility and virological outcome in nucleoside-experienced patients receiving three or four antiretroviral drugs** *AIDS*  
Katzenstein, D. A., Bosch, R. J., Hellmann, N., Wang, N., Bachelier, L., Albrecht, M. A.  
2003; 17 (6): 821-830
- **Polymorphism in HIV-1 non-subtype B protease and reverse transcriptase and its potential impact on drug susceptibility and drug resistance evolution.** *AIDS reviews*  
Kantor, R., Katzenstein, D.  
2003; 5 (1): 25-35
- **Prognostic value of baseline human immunodeficiency virus type 1 DNA measurement for disease progression in patients receiving nucleoside therapy** *JOURNAL OF INFECTIOUS DISEASES*  
Tierney, C., Lathey, J. L., Christopherson, C., Bettendorf, D. M., D'Aquila, R. T., Hammer, S. M., Katzenstein, D. A.  
2003; 187 (1): 144-148
- **HIV-1 subtype C reverse transcriptase and protease genotypes in Zimbabwean patients failing antiretroviral therapy** *AIDS RESEARCH AND HUMAN RETROVIRUSES*  
Kantor, R., Zijenah, L. S., Shafer, R. W., Mutetwa, S., Johnston, E., Lloyd, R., Von Lieven, A., Israelski, D., Katzenstein, D. A.  
2002; 18 (18): 1407-1413
- **Association of high HIV-1 RNA levels and homozygosity at HLA class II DRB1 in adults coinfecting with Mycobacterium tuberculosis in Harare, Zimbabwe** *HUMAN IMMUNOLOGY*  
Zijenah, L. S., Hartogensis, W. E., Katzenstein, D. A., Tobaiwa, O., Mutswangwa, J., Mason, P. R., Louie, L. G.  
2002; 63 (11): 1026-1032
- **Subtle decreases in stavudine phenotypic susceptibility predict poor virologic response to stavudine monotherapy in zidovudine-experienced patients** *1st IAS Conference on HIV Pathogenesis and Treatment*  
Shulman, N. S., Hughes, M. D., Winters, M. A., Shafer, R. W., Zolopa, A. R., Hellmann, N. S., Bates, M., Whitcomb, J. M., Katzenstein, D. A.  
LIPPINCOTT WILLIAMS & WILKINS.2002: 121-27
- **Durability of response to treatment among antiretroviral-experienced subjects: 48-week results from AIDS Clinical Trials Group Protocol 359** *7th Conference on Retroviruses and Opportunistic Infections*  
Gulick, R. M., Hu, X. J., Fiscus, S. A., Fletcher, C. V., Haubrich, R., Cheng, H. L., Acosta, E., Lagakos, S. W., Swanstrom, R., Freimuth, W., Snyder, S., Mills, C., Fischl, et al  
UNIV CHICAGO PRESS.2002: 626-33
- **Antiretroviral treatment for adult HIV infection in 2002 - Updated recommendations of the international AIDS Society-USA panel** *JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION*  
Yeni, P. G., Hammer, S. M., Carpenter, C. C., Cooper, D. A., Fischl, M. A., Gatell, J. M., Gazzard, B. G., Hirsch, M. S., Jacobsen, D. M., Katzenstein, D. A., Montaner, J. S., Richman, D. D., Saag, et al



2002; 288 (2): 222-235

- **A phase I, placebo-controlled trial of multi-dose recombinant human interleukin-12 in patients with HIV infection** *AIDS*  
Jacobson, M. A., Spritzler, J., Landay, A., Chan, E., KATZENSTEIN, D., Schock, B., Fox, L., Roe, J., Kundu, S., Pollard, R.  
2002; 16 (8): 1147-1154
- **Clinical signs and symptoms in the assessment of immunodeficiency in men with subtype C HIV infection in Harare, Zimbabwe.** *HIV clinical trials*  
Machekano, R., Bassett, M., McFarland, W., Katzenstein, D.  
2002; 3 (2): 148-154
- **Clinical impact of the M184V mutation on switching to didanosine or maintaining lamivudine treatment in nucleoside-experienced patients**  
Winters, M. A., Bosch, R. J., Albrecht, M. A., Katzenstein, D. A.  
INT MEDICAL PRESS LTD.2002: S134-S134
- **Evolution of protease phenotype and genotype changes at initial and continued virological failure among nucleoside-experienced subjects receiving nelfinavir in ACTG 364**  
KATZENSTEIN, D., Downey, G., Bosch, R., Hellmann, N., Becker, M., Albrecht, M.  
INT MEDICAL PRESS LTD.2002: S156-S156
- **Genotypic correlates of a virologic response to stavudine after zidovudine monotherapy** *JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES*  
Shulman, N. S., Machekano, R. A., Shafer, R. W., Winters, M. A., Zolopa, A. R., Liou, S. H., Hughes, M., Katzenstein, D. A.  
2001; 27 (4): 377-380
- **Phenotypic hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in treatment-experienced HIV-infected patients: impact on virological response to efavirenz-based therapy** *AIDS*  
Shulman, N., Zolopa, A. R., Passaro, D., Shafer, R. W., Huang, W., KATZENSTEIN, D., Israelski, D. M., Hellmann, N., Petropoulos, C., Whitcomb, J.  
2001; 15 (9): 1125-1132
- **Virologic and CD4 cell response to zidovudine or zidovudine and lamivudine following didanosine treatment of human immunodeficiency virus infection** *AIDS RESEARCH AND HUMAN RETROVIRUSES*  
Katzenstein, D. A., Hughes, M. D., Albrecht, M., Liou, S. H., Murphy, R., BALFOUR, H., Para, M., Hammer, S.  
2001; 17 (3): 203-210
- **Vertical transmission of HIV in Africa: diagnostic testing and new interventions.** *HIV clinical trials*  
KATZENSTEIN, D.  
2000; 1 (3): 51-57
- **Randomized study of saquinavir with ritonavir or nelfinavir together with delavirdine, adefovir, or both in human immunodeficiency virus-infected adults with virologic failure on indinavir: AIDS Clinical Trials Group study 359** *JOURNAL OF INFECTIOUS DISEASES*  
Gulick, R. M., Hu, X. J., Fiscus, S. A., Fletcher, C. V., Haubrich, R., Cheng, H. L., Acosta, E., Lagakos, S. W., Swanstrom, R., Freimuth, W., Snyder, S., Mills, C., Fischl, et al  
2000; 182 (5): 1375-1384
- **HIV type 1 envelope subtype C sequences from recent seroconverters in Zimbabwe** *AIDS RESEARCH AND HUMAN RETROVIRUSES*  
Batra, M., Tien, P. C., Shafer, R. W., Contag, C. H., Katzenstein, D. A.  
2000; 16 (10): 973-979
- **Virologic and CD4(+) cell responses to new nucleoside regimens: switching to stavudine or adding lamivudine after prolonged zidovudine treatment of human immunodeficiency virus infection** *AIDS RESEARCH AND HUMAN RETROVIRUSES*  
Katzenstein, D. A., Hughes, M., Albrecht, M., Hammer, S., Para, M., Murphy, R., Valdez, H., Haubrich, R., Liou, S.  
2000; 16 (11): 1031-1037
- **Efavirenz- and adefovir dipivoxil-based salvage therapy in highly treatment-experienced patients: Clinical and genotypic predictors of virologic response** *JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES*  
Shulman, N. S., Zolopa, A. R., Passaro, D. J., Murlidharan, U., Israelski, D. M., Brosgart, C. L., Miller, M. D., Van Doren, S., Shafer, R. W., Katzenstein, D. A.  
2000; 23 (3): 221-226
- **HIV-1 genotypic resistance patterns predict response to saquinavir-ritonavir therapy in patients in whom previous protease inhibitor therapy had failed** *ANNALS OF INTERNAL MEDICINE*  
Zolopa, A. R., Shafer, R. W., Warford, A., Montoya, J. G., Hsu, P., KATZENSTEIN, D., Merigan, T. C., Efron, B.  
1999; 131 (11): 813-?



- **Delayed-type hypersensitivity to recombinant HIV envelope glycoprotein (rgp160) after immunization with homologous antigen** *JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES*  
Katzenstein, D. A., Kundu, S., Spritzler, J., SMOLLER, B. R., Haszlett, P., Valentine, F., Merigan, T. C.  
1999; 22 (4): 341-347
- **The contribution of assay variation and biological variation to the total variability of plasma HIV-1 RNA measurements** *AIDS*  
Brambilla, D., REICHELDERFER, P. S., Bremer, J. W., Shapiro, D. E., Hershow, R. C., Katzenstein, D. A., Hammer, S. M., Jackson, B., Collier, A. C., Sperling, R. S., Fowler, M. G., COOMBS, R. W.  
1999; 13 (16): 2269-2279
- **Serum level of maternal human immunodeficiency virus (HIV) RNA, infant mortality, and vertical transmission of HIV in Zimbabwe** *Conference on Global Strategies for the Prevention of HIV Transmission from Mothers to Infants*  
Katzenstein, D. A., Mbizvo, M., Zijenah, L., Gittens, T., Munjoma, M., Hill, D., Madzime, S., Maldonado, Y.  
UNIV CHICAGO PRESS.1999: 1382-87
- **Primary subtype C HIV-1 infection in Harare, Zimbabwe** *JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES*  
Tien, P. C., Chiu, T., Latif, A., Ray, S., Batra, M., Contag, C. H., Zejena, L., Mbizvo, M., Delwart, E. L., Mullins, J. I., Katzenstein, D. A.  
1999; 20 (2): 147-153
- **Detection of Kaposi's sarcoma-associated herpesvirus in peripheral blood cells in human immunodeficiency virus infection: Association with Kaposi's sarcoma, CD4 cell count, and HIV RNA levels** *AIDS RESEARCH AND HUMAN RETROVIRUSES*  
Min, J., Katzenstein, D. A.  
1999; 15 (1): 51-55
- **Sequence and drug susceptibility of subtype C protease from human immunodeficiency virus type 1 seroconverters in Zimbabwe** *AIDS RESEARCH AND HUMAN RETROVIRUSES*  
Shafer, R. W., Chuang, T. K., Hsu, P., White, C. B., Katzenstein, D. A.  
1999; 15 (1): 65-69
- **Neuromuscular function in HIV infection: analysis of a placebo-controlled combination antiretroviral trial** *AIDS*  
Simpson, D. M., Katzenstein, D. A., Hughes, M. D., Hammer, S. M., Williamson, D. L., Jiang, Q., Pi, J. T.  
1998; 12 (18): 2425-2432
- **The extent of non-adherence in a large AIDS clinical trial using plasma dideoxynucleoside concentrations as a marker** *95th Annual Meeting of the American-Society-of-Clinical-Pharmacology*  
Kastrissios, H., Suarez, J. R., Hammer, S., KATZENSTEIN, D., Blaschke, T. F.  
LIPPINCOTT WILLIAMS & WILKINS.1998: 2305-11
- **Characterizing patterns of drug-taking behavior with a multiple drug regimen in an AIDS clinical trial** *96th Annual Meeting of the American-Society-of-Clinical-Pharmacology*  
Kastrissios, H., Suarez, J. R., KATZENSTEIN, D., GIRARD, P., Sheiner, L. B., Blaschke, T. F.  
LIPPINCOTT WILLIAMS & WILKINS.1998: 2295-2303
- **A 6-basepair insert in the reverse transcriptase gene of human immunodeficiency virus type 1 confers resistance to multiple nucleoside inhibitors** *2nd International Workshop on HIV Drug Resistance and Treatment Strategies*  
Winters, M. A., Coolley, K. L., Girard, Y. A., Levee, D. J., Hamdan, H., Shafer, R. W., Katzenstein, D. A., Merigan, T. C.  
AMER SOC CLINICAL INVESTIGATION INC.1998: 1769-75
- **Mortality in the first 2 years among infants born to human immunodeficiency virus-infected women in Harare, Zimbabwe** *4th Conference on Retroviruses and Opportunistic Infections*  
Zijenah, L., Mbizvo, M. T., Kasule, J., Nathoo, K., Munjoma, M., Mahomed, K., Maldonado, Y., Madzime, S., Katzenstein, D.  
OXFORD UNIV PRESS INC.1998: 109-13
- **Geographic and demographic differences in the frequency of human cytomegalovirus gB genotypes 1-4 in immunocompromised patients** *AIDS RESEARCH AND HUMAN RETROVIRUSES*  
Zipeto, D., Hong, C., Gerna, G., Zavattoni, M., KATZENSTEIN, D., Merigan, T. C., Rasmussen, L.  
1998; 14 (6): 533-536
- **Human immunodeficiency virus type 1 RNA shedding in the female genital tract** *JOURNAL OF INFECTIOUS DISEASES*  
Goulston, C., McFarland, W., KATZENSTEIN, D.  
1998; 177 (4): 1100-1103

- **HIV-1 reverse transcriptase codon 215 mutation in plasma RNA: Immunologic and virologic responses to zidovudine** *JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES*  
Rey, D., Hughes, M., Pi, J. T., Winters, M., Merigan, T. C., Katzenstein, D. A.  
1998; 17 (3): 203-208
- **Polymerase chain reaction detection of Haemophilus ducreyi DNA** *SEXUALLY TRANSMITTED INFECTIONS*  
Roesel, D. J., Gwanzura, L., Mason, P. R., Joffe, M., Katzenstein, D. A.  
1998; 74 (1): 63-65
- **Use of changes in plasma levels of human immunodeficiency virus type 1 RNA to assess the clinical benefit of antiretroviral therapy** *JOURNAL OF INFECTIOUS DISEASES*  
Marschner, I. C., Collier, A. C., COOMBS, R. W., D'Aquila, R. T., DeGruttola, V., Fischl, M. A., Hammer, S. M., Hughes, M. D., JOHNSON, V. A., Katzenstein, D. A., Richman, D. D., Smeaton, L. M., Spector, et al  
1998; 177 (1): 40-47
- **Combination therapies for HIV infection and genomic drug resistance** *LANCET*  
KATZENSTEIN, D.  
1997; 350 (9083): 970-971
- **Effect of therapeutic immunization with recombinant gp160 HIV-1 vaccine on HIV-1 proviral DNA and plasma RNA: Relationship to cellular immune responses** *JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES*  
Kundu, S. K., KATZENSTEIN, D., Valentine, F. T., Spino, C., Efron, B., Merigan, T. C.  
1997; 15 (4): 269-274
- **Measuring quality of life in early HIV disease: the modular approach** *QUALITY OF LIFE RESEARCH*  
Lenderking, W. R., Testa, M. A., KATZENSTEIN, D., Hammer, S.  
1997; 6 (6): 515-530
- **Sequence and drug susceptibility of subtype C reverse transcriptase from human immunodeficiency virus type 1 seroconverters in Zimbabwe** *JOURNAL OF VIROLOGY*  
Shafer, R. W., Eisen, J. A., Merigan, T. C., Katzenstein, D. A.  
1997; 71 (7): 5441-5448
- **Antiretroviral therapy for human immunodeficiency virus infection in 1997** *WESTERN JOURNAL OF MEDICINE*  
Katzenstein, D. A.  
1997; 166 (5): 319-325
- **HIV therapeutics: confronting adherence.** *journal of the Association of Nurses in AIDS Care : JANAC*  
Katzenstein, D. A., Lyons, C., Molaghan, J. P., UNGVARSKI, P., Wolfe, G. S., Williams, A.  
1997; 8: 46-58
- **Adherence as a particular issue with protease inhibitors.** *journal of the Association of Nurses in AIDS Care : JANAC*  
Katzenstein, D. A.  
1997; 8: 10-17
- **The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter** *NEW ENGLAND JOURNAL OF MEDICINE*  
Katzenstein, D. A., Hammer, S. M., Hughes, M. D., Gundacker, H., Jackson, J. B., Fiscus, S., Rasheed, S., Elbeik, T., REICHMAN, R., Japour, A., Merigan, T. C., Hirsch, M. S.  
1996; 335 (15): 1091-1098
- **A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter** *NEW ENGLAND JOURNAL OF MEDICINE*  
Hammer, S. M., Katzenstein, D. A., Hughes, M. D., Gundacker, H., Schooley, R. T., Haubrich, R. H., Henry, W. K., Lederman, M. M., Phair, J. P., Niu, M., Hirsch, M. S., Merigan, T. C., Blaschke, et al  
1996; 335 (15): 1081-1090
- **Human immunodeficiency virus in plasma and genital secretions during the menstrual cycle** *JOURNAL OF INFECTIOUS DISEASES*  
Goulston, C., Stevens, E., Gallo, D., Mullins, J. I., Hanson, C. V., KATZENSTEIN, D.  
1996; 174 (4): 858-861

- **Polyethylene glycol-modified interleukin-2 and thymosin alpha(1) in human immunodeficiency virus type 1 infection** *JOURNAL OF INFECTIOUS DISEASES*  
Ramachandran, R., Katzenstein, D. A., Winters, M. A., Kundu, S. K., Merigan, T. C.  
1996; 173 (4): 1005-1008
- **DRUG-RESISTANCE AND HETEROGENEOUS LONG-TERM VIROLOGICAL RESPONSES OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE 1-INFECTED SUBJECTS TO ZIDOVUDINE AND DIDANOSINE COMBINATION THERAPY** *JOURNAL OF INFECTIOUS DISEASES*  
Shafer, R. W., Iversen, A. K., Winters, M. A., Aguiniga, E., Katzenstein, D. A., Merigan, T. C.  
1995; 172 (1): 70-78
- **HIV viral load quantification, HIV resistance, and antiretroviral therapy.** *AIDS clinical review*  
Katzenstein, D. A., Holodniy, M.  
1995: 277-303
- **VIRAL PHENOTYPE AND GENOTYPE AS MARKERS IN CLINICAL-TRIALS** *1st Annual Symposium on Surrogate Markers of HIV - Strategies and Issues for Selection and Use*  
Katzenstein, D. A.  
LIPPINCOTT WILLIAMS & WILKINS.1995: S25-S34
- **FAILURE OF SHORT-TERM CD4-PE40 INFUSIONS TO REDUCE VIRUS LOAD IN HUMAN IMMUNODEFICIENCY VIRUS-INFECTED PERSONS** *JOURNAL OF INFECTIOUS DISEASES*  
Ramachandran, R. V., Katzenstein, D. A., Wood, R., Batts, D. H., Merigan, T. C.  
1994; 170 (4): 1009-1013
- **DIDANOSINE RESISTANCE IN HIV-INFECTED PATIENTS SWITCHED FROM ZIDOVUDINE TO DIDANOSINE MONOTHERAPY** *ANNALS OF INTERNAL MEDICINE*  
Kozal, M. J., Kroodsm, K., Winters, M. A., Shafer, R. W., Efron, B., Katzenstein, D. A., Merigan, T. C.  
1994; 121 (4): 263-268
- **HIV-1 SYNCYTIUM-INDUCING PHENOTYPE, VIRUS BURDEN CODON-215 REVERSE-TRANSCRIPTASE MUTATION AND CD4 CELL DECLINE IN ZIDOVUDINE-TREATED PATIENTS** *JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY*  
Kozal, M. J., Shafer, R. W., Winters, M. A., Katzenstein, D. A., Aguiniga, E., Halpern, J., Merigan, T. C.  
1994; 7 (8): 832-838
- **COMBINATION THERAPY WITH ZIDOVUDINE AND DIDANOSINE SELECTS FOR DRUG-RESISTANT HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 STRAINS WITH UNIQUE PATTERNS OF POL GENE-MUTATIONS** *JOURNAL OF INFECTIOUS DISEASES*  
Shafer, R. W., Kozal, M. J., Winters, M. A., Iversen, A. K., Katzenstein, D. A., Ragni, M. V., Meyer, W. A., Gupta, P., Rasheed, S., COOMBS, R., Katzman, M., Fiscus, S., Merigan, et al  
1994; 169 (4): 722-729
- **QUANTITATION OF HUMAN-IMMUNODEFICIENCY-VIRUS BY CULTURE AND POLYMERASE CHAIN-REACTION IN RESPONSE TO DIDANOSINE AFTER LONG-TERM THERAPY WITH ZIDOVUDINE** *JOURNAL OF INFECTIOUS DISEASES*  
Katzenstein, D. A., Winters, M., BUBP, J., Israelski, D., Winger, E., Merigan, T. C.  
1994; 169 (2): 416-419
- **BIOLOGICAL VARIATION AND QUALITY-CONTROL OF PLASMA HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 RNA QUANTITATION BY REVERSE-TRANSCRIPTASE POLYMERASE CHAIN-REACTION** *JOURNAL OF CLINICAL MICROBIOLOGY*  
Winters, M. A., Tan, L. B., Katzenstein, D. A., Merigan, T. C.  
1993; 31 (11): 2960-2966
- **PERIPHERAL-BLOOD MONONUCLEAR CELL HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 PROVIRAL DNA QUANTIFICATION BY POLYMERASE CHAIN-REACTION - RELATIONSHIP TO IMMUNODEFICIENCY AND DRUG EFFECT** *JOURNAL OF CLINICAL MICROBIOLOGY*  
Montoya, J. G., Wood, R., KATZENSTEIN, D., HOLODNY, M., Merigan, T. C.  
1993; 31 (10): 2692-2696
- **MEASUREMENT OF HIV VIRUS LOAD AND GENOTYPIC RESISTANCE BY GENE AMPLIFICATION IN ASYMPTOMATIC SUBJECTS TREATED WITH COMBINATION THERAPY** *JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES*  
Holodniy, M., KATZENSTEIN, D., Winters, M., Montoya, J., Shafer, R., Kozal, M., Ragni, M., Merigan, T. C.  
1993; 6 (4): 366-369

- **DETECTION OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 IN SEMEN - EFFECTS OF DISEASE STAGE AND NUCLEOSIDE THERAPY** *JOURNAL OF INFECTIOUS DISEASES*  
Hamed, K. A., Winters, M. A., Holodniy, M., Katzenstein, D. A., Merigan, T. C.  
1993; 167 (4): 798-802
- **A MUTATION IN HUMAN-IMMUNODEFICIENCY-VIRUS REVERSE-TRANSCRIPTASE AND DECLINE IN LYMPHOCYTE-CD4 NUMBERS IN LONG-TERM ZIDOVUDINE RECIPIENTS** *JOURNAL OF INFECTIOUS DISEASES*  
Kozal, M. J., Shafer, R. W., Winters, M. A., Katzenstein, D. A., Merigan, T. C.  
1993; 167 (3): 526-532
- **ZIDOVUDINE SUSCEPTIBILITY TESTING OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 (HIV) CLINICAL ISOLATES** *JOURNAL OF VIROLOGICAL METHODS*  
Shafer, R. W., Kozal, M. J., Katzenstein, D. A., LIPIL, W. H., JOHNSTONE, I. F., Merigan, T. C.  
1993; 41 (3): 297-310
- **QUANTIFICATION AND COMPARISON OF HIV-1 PROVIRAL LOAD IN PERIPHERAL-BLOOD MONONUCLEAR-CELLS AND ISOLATED CD4+ T-CELLS** *JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES*  
Wood, R., Dong, H. L., Katzenstein, D. A., Merigan, T. C.  
1993; 6 (3): 237-240
- **ENHANCEMENT OF HUMAN-IMMUNODEFICIENCY-VIRUS (HIV)-SPECIFIC CD4+ AND CD8+ CYTOTOXIC LYMPHOCYTE-T ACTIVITIES IN HIV-INFECTED ASYMPTOMATIC PATIENTS GIVEN RECOMBINANT GP160 VACCINE** *PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA*  
Kundu, S. K., KATZENSTEIN, D., Moses, L. E., Merigan, T. C.  
1992; 89 (23): 11204-11208
- **Quantitative RNA and DNA gene amplification can rapidly monitor HIV infection and antiviral activity in cell cultures.** *PCR methods and applications*  
Winters, M. A., Holodniy, M., Katzenstein, D. A., Merigan, T. C.  
1992; 1 (4): 257-262
- **PLASMA VIREMIA IN HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION - RELATIONSHIP TO STAGE OF DISEASE AND ANTIVIRAL TREATMENT** *JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY*  
Katzenstein, D. A., Holodniy, M., Israelski, D. M., Sengupta, S., Mole, L. A., BUBP, J. L., Merigan, T. C.  
1992; 5 (2): 107-112
- **DECREASE IN HIV PROVIRUS IN PERIPHERAL-BLOOD MONONUCLEAR-CELLS DURING ZIDOVUDINE AND HUMAN RIL-2 ADMINISTRATION** *JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY*  
Clark, A. G., Holodniy, M., Schwartz, D. H., Katzenstein, D. A., Merigan, T. C.  
1992; 5 (1): 52-59
- **Quantitative virological measures of antiretroviral therapy.** *AIDS clinical review*  
Katzenstein, D. A., Holodniy, M.  
1992: 41-67
- **REDUCTION IN PLASMA HUMAN-IMMUNODEFICIENCY-VIRUS RIBONUCLEIC-ACID AFTER DIDEOXYNUCLEOSIDE THERAPY AS DETERMINED BY THE POLYMERASE CHAIN-REACTION** *JOURNAL OF CLINICAL INVESTIGATION*  
Holodniy, M., Katzenstein, D. A., Israelski, D. M., Merigan, T. C.  
1991; 88 (5): 1755-1759
- **DETECTION OF HUMAN-IMMUNODEFICIENCY-VIRUS DNA AND RNA IN SEMEN BY THE POLYMERASE CHAIN-REACTION** *JOURNAL OF INFECTIOUS DISEASES*  
Mermin, J. H., Holodniy, M., Katzenstein, D. A., Merigan, T. C.  
1991; 164 (4): 769-772
- **INHIBITION OF HUMAN-IMMUNODEFICIENCY-VIRUS GENE AMPLIFICATION BY HEPARIN** *JOURNAL OF CLINICAL MICROBIOLOGY*  
Holodniy, M., Kim, S., KATZENSTEIN, D., Konrad, M., Groves, E., Merigan, T. C.  
1991; 29 (4): 676-679
- **DETECTION AND QUANTIFICATION OF HUMAN-IMMUNODEFICIENCY-VIRUS RNA IN PATIENT SERUM BY USE OF THE POLYMERASE CHAIN-REACTION** *JOURNAL OF INFECTIOUS DISEASES*  
Holodniy, M., Katzenstein, D. A., Sengupta, S., Wang, A. M., CASIPIT, C., Schwartz, D. H., Konrad, M., Groves, E., Merigan, T. C.

1991; 163 (4): 862-866

- **RELATION OF THE PATHOGENESIS OF HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION TO VARIOUS STRATEGIES FOR ITS CONTROL** *REVIEWS OF INFECTIOUS DISEASES*

Merigan, T. C., Katzenstein, D. A.

1991; 13 (2): 292-302